Survey
* Your assessment is very important for improving the work of artificial intelligence, which forms the content of this project
* Your assessment is very important for improving the work of artificial intelligence, which forms the content of this project
Morning Report 10/26/16 Annie Belzwoski, MD PGY2 60 y/o Female w/ body aches, and cough Morning report 10/26/16 In the Emergency Room… Initial VS: 37.2, 93, 108/68, 20, 92% RA Gen: thin, frail, elderly woman, lying very still in bed. calm, pleasant. HEENT: No conjunctival injection or scleral icterus. Conjunctival pallor. PERRLA, EOMI. No frontal or maxillary tenderness. No OP erythema. No cervical LAD. Neck: Flat JVD, no thyromegaly Chest: RRR. 3/6 systolic murmur best heard oat RUSB, no radiation to carotids. Lungs: CTAB, no wheezes or crackles Abd: +BS, soft, nd, nt, no organomegaly Ext: 2+ radial, dp, pt, pulses b/l. No edema No rheumatoid nodules in elbows. Ulnar deviation in hands bilaterally. MCPs, PIPs, DIPs notender to palpation. Neuro: No sensory or motor deficits. Toes downgoing bilaterally Initial Labs JUL 28 15:27 L 133 | L 96 | 9 / _____________________ 85 5.0 | 29 | 0.53 \ \ L 7.6 / H 24.9 _______ H 956 / L 24.8 \ ESR 98 CRP 259.5 Lipase 17 Lactate 1.1 UA neg Alk Phos 172 Alb 2.0 Imaging CXR 7/28/16 XR Chest No definite acute cardiopulmonary process. If clinical suspicion for pneumonia is high, recommend follow-up two view chest radiograph and/or treatment based on symptomatology. Scattered calcified and noncalcified pulmonary nodules as well as a focal left hemithoracic pleural thickening are nonspecific but can be seen with sequelae of old granulomatous disease. CT Chest Abdomen w/Contrast IMPRESSION: Large right lower lobe lung abscess measuring up to 8.4 cm with surrounding right lower lobe consolidation, additional micro microabscesses, mucus plugging and broncholiths. Rightsided pleural effusion appears transudative. Underlying pulmonary tuberculosis cannot be excluded. Alternatively, the possibility of a large pulmonary neoplasm cannot entirely be excluded. Recommend correlation with cytology if pulmonary abscess is drained. Centrilobular nodularity in the left lung is nonspecific but may represent endobronchial spread of infection Enlarged necrotic hilar and mediastinal lymph nodes, likely secondary to pulmonary infection, less likely secondary to malignancy. No CT evidence for mastectomy. Consider correlation with clinical history. Right thyroid lobe nodule. Nonspecific cystic lesions in the spleen. They do not have the appearance of micro abscess sees. Differential considerations include focal splenic abscesses versus splenic cysts. 7.4 cm left adnexal cyst. Given the patient's age gynecology consultation is suggested if indicated. Evidence of old granulomatous disease in the lungs, hila and liver. Osteopenia and multiple probable vertebral body hemangiomas. Nonspecific gallbladder wall thickening. Clinical correlation for acute cholecystitis. ECHO ECHO Summary: 1. Left ventricle: Systolic function is normal. The estimated ejection fraction is 65-70%. Features are consistent with a pseudonormal left ventricular filling pattern, with concomitant abnormal relaxation and increased filling pressure (grade 2 diastolic dysfunction). 2. Pericardium, extracardiac: A small pericardial effusion is identified. There is no evidence of cardiac tamponade. 3. Large left pleural effusion. 4. Right atrial pressure is estimated at 3 mmHg and Pulmonary pressures are estimated to be 31mmHg. 5. To the extent visualized there is no evidence of valvular vegetations. Recommend TEE if clinically indicated. Micro Crypto neg Aspergilllus Neg Cocci neg Echinococcus Neg Resp Cx Gram Stain Few Gram Positive Cocci Few White Blood Cells Rare epithelial cells Brucella Ab Neg AFB neg x3 MTB-PCR neg x2 PCP DFA neg Blood cultures Neg x 4 dayts Resp Cx Gram Stain Rare White Blood Cells Few epithelial cells Few Gram Positive Cocci Rare Gram Positive Rods Rare Gram Negative Rods MRSA neg Resp Culture Neg Acid Fast, fungal cultures Bronchoscopy Normal mucosia and patent airways on the left. Right upper lobe with normal mucosa and airways. RML airway with small amount of airway compression. RLL airway completely compressed with abnormal moderately noduler mucosa, see images. RLL superior segment with moderate airway compression but BAL performed in this segment Pathology Right lower lobe of lung (endobronchial biopsy): - Invasive keratinizing squamous cell carcinoma, moderately differentiated. - Immunostains: CK5/6- positive; p63- positive; TTF-1- negative (pattern supports the above diagnosis) Bronchoalveolar lavage, RLL (cytology): - Rare atypical squamous cells - Alveolar macrophages, some pigmented in the background of mixed inflammatory cells Lung Cancer Annie Belzowski Scope In 2012, 1.8 million people were diagnosed with lung cancer and 1.6 million people died of the disease (1) According to the ACS, in 2016 there were 224,390 new cases and 158,080 deaths in the United States (2) Subtypes Less common types of lung cancer include pleomorphic, carcinoid tumor, salivary gland carcinoma, and unclassified carcinoma Wistuba I, Brambilla E, Noguchi M. Chapter 17: Classic Anatomic Pathology and Lung Cancer. In: Pass HI, Ball D, Scagliotti GV, eds. The IASLC Multidisciplinary Approach to Thoracic Oncology. Aurora, CO: IASLC Press; 2014:217-240. via https://www.lungevity.org/about-lung-cancer/lungcancer-101/types-of-lung-cancer Risk Factors Smoking: Accounts for 90% of all Lung cancers Radiation Therapy: Hodkins and breask cancer Environmental Toxins: second hand smoke, asbestos, radon and metas (Arsenic, chromium and nickel), ionizing radiation and polycyclic aromtc hydrocarbons Pulmonary Fibrosis HIV Infection Genetic factors Alcohol Dietary factors 3 A Note about Screening CXR and sputum cytology DO NOT reduce mortality from lung cancer National Lung Screening Trial compared CT screening with Chest XRAY 20% decrease in lung CA mortality in heavy smokers who were screening annually for three years and is only trial to show benefit in mortality reduction USPSTF low dose CT scanning a B recommendation for those with high risk CMS requirements 3 55-77 years of age No symptoms of lung cancer 30 pack year smoking history If they have quit have done so within 15 years Clinical Manifestations Local effects Spread Paraneoplastic syndromes Local Effects Cough (45-74%) Hemoptysis (27-29%) Chest pain (27-49%) Dyspnea (37-58%) Hoarseness (8-18%) Pleural Involvement Superior Vena Cava Syndrome Pancoast Syndrome 3, 4 Extrathorasic Metastasis Liver Adrenal Glands Bones Brain Paraneoplastic syndromes Hypercalcemia SIADH Neurologic Hematological manifestations Hypertrophic Osteoarthropathy Dermatomyositis and Polymyositis Crushing Syndromes Staging 5, 6 Bone Scan IMPRESSION: 1. Multiple foci of moderate uptake within the bilateral ribs are suspicious for osseous metastases. 2. Focal increased uptake within the right posterior 4th and 5th ribs and right inferolateral ribs in a vertical alignment may be related to prior trauma. Evaluation NSCLC: non-small cell lung cancer; RT: radiation therapy; SBRT: stereotactic body radiation therapy. * Based upon comorbidities, age, or refusal of surgery. ¶ SBRT preferred for tumors <5 cm; definitive RT with conventional fractionation for larger lesions. Δ Primarily for tumors >4 cm; observation is an alternative. ◊ Consultation with medical oncology, radiation oncology, and thoracic surgery indicated prior to definitive therapy. Concurrent chemoradiotherapy, surgery, or induction therapy followed by resection in carefully selected patients. 7 Prognosis Overall survival by TNM grouping, non-small cell lung cancer 7 Goldstraw P, Crowley J, Chansky K, et al. The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours. J Thorac Oncol 2007; 2:706. Copyright © 2007 Lippincott Williams & Wilkins. Graphic 73088 Version 14.0 References 1. Brambilla E, Travis WD. Lung cancer. In: World Cancer Report, Stewart BW, Wild CP (Eds), World Health Organization, Lyon 2014. 2. “Cancer Statistics” CA Cancer J Clin. 2016 Jan-Feb;66(1):7-30. doi: 10.3322/caac.21332. Epub 2016 Jan 7. 3. Midthun D , Lilenbaum, R, Vora,S “Overview of the risk factors, pathology, and clinical manifestations of lung cancer”, PubMed, Feb, 2015 4. Hyde, L, Hyde, Symptoms of lung cancer in over 3500 patients at presentation CI. Chest 1974; 65:299-306 and Chute CG, et al. Cancer 1985; 56:2107-2111. Graphic 76229 Version 1.0 5. Nasser, “The Best Oncologist” http://www.thebestoncologist.com/Cancer_Diseases/Lung_Cancer/Staging_of _Lung_Cancer.html 2010 6. Thomas, K, Gould M, “Overview of the initial evaluation, diagnosis, and staging of patients with suspected lung cancer” Pub Med, July 2016 7. West, H, Vallieres, E, Schlid, S “Management of stage I and stage II non-small cell lung cancer”, PubMed, Oct 2016